Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy

de Oliveira Andrade, Luis Jesuino; Atta, Ajax Mercês; de Sousa Atta, Maria Luiza Brito; Mangabeira, Célia Neder Kalil; Paraná, Raymundo

doi:10.1016/S1413-8670(11)70208-2

Article information

Abstract

Objective

To investigate the frequency of thyroid disorders (TD) in patients with chronic hepatitis C before and during interferon-alpha (IFN-α) and ribavirin (RIB) treatment.

Study design

Prospective study.

Patients and Methods

We prospectively studied 65 anti-HCV and viral RNA positive patients. Free thyroxine, thyroid-stimulating hormone, and thyroid peroxidase antibodies (TPO-Ab) were systematically tested at entry (m0), week 12 (m3) and week 24 (m6) of treatment.

Results

Mean age of the 65 patients (38 females and 27 males) was 49.61±11.83 years. Seven (10.76%) patients presented baseline thyroid disorders (m0), three had thyroid dysfunction, and four were TPO-Ab positive. Thyroid disorders occurred in the first 12 weeks of treatment in 11 (16.92%) patients, four with thyroid dysfunction, and seven with TPO-Ab positive (m3). A total of 18 patients (27.69%) developed TD after 24 weeks of treatment, 7 with thyroid dysfunction, and 11 with TPO-Ab positive (m6). The relative risk of developing hypothyroidism found in this study was 1.3 (95% CI: 1.1 to 1.6), hyperthyroidism 1.2 (95% CI: 1.1 to 1.4), and TPO-Ab positivity 7.6 (95% CI: 3.9 to 14.5). The study showed a significant association between female sex and thyroid disease (p=0.009).

Conclusion

Thyroid dysfunction and autoimmune TD were observed during IFN-α and RIB therapy.

Keywords:

hepatitis C

interferon-alpha

ribavirin

thyroid diseases

autoimmunity

Full text is only aviable in PDF

References

[1.]

H.A. Tran, G.E. Reeves.

The spectrum of autoimmune thyroid disease in the short to medium term following interferon-alpha therapy for chronic hepatitis C.

Int J Endocrinol, 2009 (2009), pp. 241786

http://dx.doi.org/10.1155/2009/241786 | Medline

[2.]

Y. Tomer, F. Menconi.

Interferon induced thyroiditis.

Best Pract Res Clin Endocrinol Metab, 23 (2009), pp. 703-712

http://dx.doi.org/10.1016/j.beem.2009.07.004 | Medline

[3.]

A. Antonelli, C. Ferri, P. Fallahi.

Hepatitis C:thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy.

Nat Rev Gastroenterol Hepatol, 6 (2009), pp. 633-635

http://dx.doi.org/10.1038/nrgastro.2009.168 | Medline

[4.]

Y. Tomer, J.T. Blackard, N. Akeno.

Interferon alpha treatment and thyroid dysfunction.

Endocrinol Metab Clin North Am, 36 (2007), pp. 1051-1066

http://dx.doi.org/10.1016/j.ecl.2007.07.001 | Medline

[5.]

N.J. Snell.

Ribavirin - current status of a broad spectrum antiviral agent.

Expert Opin Pharmacother, 2 (2001), pp. 1317-1324

http://dx.doi.org/10.1517/14656566.2.8.1317 | Medline

[6.]

R.C. Tam, C. Lim, J. Bard, B. Pai.

Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by type 1 cytokine polarization, regulation of IL-10 expression, and costimulatory signaling.

J Immunol, 163 (1999), pp. 3709-3717

Medline

[7.]

L.K. Koh, F.S. Greenspan, P.P. Yeo.

Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature.

Thyroid, 7 (1997), pp. 891-896

http://dx.doi.org/10.1089/thy.1997.7.891 | Medline

[8.]

H.A. Tran, G.E. Reeves.

The influence of hepatitis C infection and interferon-alpha therapy on thyrotropin blocking and stimulating autoantibodies in Graves ophthalmopathy: a case report.

Thyroid Res, 2 (2009), pp. 12

http://dx.doi.org/10.1186/1756-6614-2-12 | Medline

[9.]

A.L. Zignego, A. Craxì.

Extrahepatic manifestations of hepatitis C virus infection.

Clin. Liver Dis, 12 (2008), pp. 611-636

http://dx.doi.org/10.1016/j.cld.2008.03.012 | Medline

[10.]

J. Bartolomé, E. Rodríguez-Iñigo, P. Quadros, et al.

Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection.

J Med Virol, 80 (2008), pp. 1588-1594

http://dx.doi.org/10.1002/jmv.21269 | Medline

[11.]

P. Simmonds, F. McOmish, P.L. Yap, et al.

Sequence variability in the 5 non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

J Gen Virol, 74 (1993), pp. 661-668

http://dx.doi.org/10.1099/0022-1317-74-4-661 | Medline

[12.]

P. Bedossa, T. Poynard.

An algorithm for the grading of activity in chronic hepatitis C. The Metavir Cooperative Study Group.

Hepatology, 24 (1996), pp. 289

http://dx.doi.org/10.1002/hep.510240201 | Medline

[13.]

P. Bedossa.

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.

Hepatology, 20 (1994), pp. 15-20

Medline

[14.]

H.A. Tran, G.E. Malcolm Reeves, R. Gibson, J.R. Attia.

Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.

J Gastroenterol Hepatol, 24 (2009), pp. 1163-1168

http://dx.doi.org/10.1111/j.1440-1746.2009.05874.x | Medline

[15.]

M.F. Prummel, P. Laurberg.

Interferon-α and Autoimmune Thyroid Disease.

Thyroid, 13 (2003), pp. 547-551

http://dx.doi.org/10.1089/105072503322238809 | Medline

[16.]

E.J. Bini, S. Mehandru.

Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.

Arch Intern Med, 164 (2004), pp. 2371-2376

http://dx.doi.org/10.1001/archinte.164.21.2371 | Medline